Search
MF-300
go.drugbank.com/drugs/DB32060InvestigationalAs a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983] … MF-300 is an investigational, first-in-class, small molecule inhibitor of 15-hydroxyprostaglandin dehydrogenase.
Sparfloxacin
go.drugbank.com/drugs/DB01208ApprovedWithdrawnSparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. … DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.
Tunicamycin
go.drugbank.com/drugs/DB13172ExperimentalTunicamycin blocks N-linked glycosylation (N-glycans) resulting in cell cycle arrest at the G1 phase in human cells. It is used as an experimental tool to induce unfolded protein response. … Tunicamycin is a mixture of homologous nucleoside antibiotics that inhibits the UDP-HexNAc: polyprenol-P HexNAc-1-P family of enzymes.
Burosumab
go.drugbank.com/drugs/DB14012ApprovedInvestigationalXLH is a serious disease which affects about 3,000 children and 12,000 adults in the United States. … It causes impaired bone growth and development in children and adolescents and issues with bone mineralization throughout a patient’s life [L2346].
Lurbinectedin
go.drugbank.com/drugs/DB12674ApprovedInvestigationalthe substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. … Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma,[A214325] chronic lymphocytic leukemia (CLL),[A214328] breast cancer,
Erythrityl tetranitrate
go.drugbank.com/drugs/DB01613ApprovedWithdrawnA vasodilator with general properties similar to nitroglycerin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1020)
Pefloxacin
go.drugbank.com/drugs/DB00487ApprovedA synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.
ARG098
go.drugbank.com/drugs/DB06338ExperimentalARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.